TRAW (Traws Pharma) Long-Term Debt: $0.00 Mil (As of Mar. 2026)


TRAW Traws Pharma Inc TRAW
46 GF Score
Price $0.68
GF Value $12.95
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Traws Pharma Long-Term Debt?

Traws Pharma TRAW +4.50% 46 Long-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus rates TRAW with a GF Score™ of 46/100 and a GF Value™ of $12.95 (Possible Value Trap). The stock has 4 warning signs investors should review.

Traws Pharma's Long-Term Debt for the quarter that ended in Mar. 2026 was $0.00 Mil.

Traws Pharma  (NAS:TRAW) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Traws Pharma Long-Term Debt Related Terms

Traws Pharma Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Traws Pharma's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Traws Pharma Long-Term Debt Chart

Traws Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Traws Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TRAW
46GF Score
Traws Pharma Inc TRAW
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.00 Mil mean?
Traws Pharma (TRAW) has a Long-Term Debt of $0.00 Mil as of Mar. 2026.
Is Traws Pharma's Long-Term Debt too high?
Traws Pharma's current Long-Term Debt is $0.00 Mil. Overall, Traws Pharma has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Traws Pharma's Long-Term Debt compare to ICU and INAB?
Traws Pharma's Long-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Traws Pharma's current Long-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Traws Pharma stock overvalued right now?
Based on GuruFocus' analysis, Traws Pharma (TRAW) is currently considered Possible Value Trap. The stock's GF Value™ is $12.95, compared to a current price of $0.68 — trading 94.7% below its estimated fair value. The current Long-Term Debt is $0.00 Mil. Traws Pharma's overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Traws Pharma (TRAW), the current Long-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Traws Pharma (TRAW) Overvalued in 2026?

Based on GuruFocus' analysis, Traws Pharma stock appears to be undervalued. The current stock price of $0.68 is trading 94.7% below its estimated GF Value™ of $12.95. GuruFocus considers Traws Pharma to be Possible Value Trap.

Key valuation signals for TRAW:

  • Long-Term Debt: $0.00 Mil
  • GF Value™: $12.95 vs. price of $0.68 (94.7% below fair value)
  • GF Score™: 46/100 with 4 warning signs

No single metric tells the full story. See the TRAW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Traws Pharma Business Description

Address 12 Penns Trail, Newtown, PA, USA, 18940
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
46GF Score

Get the complete analysis for TRAW

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.68
Price
$12.95
GF Value